BeiGene Announces Approval of PARP Inhibitor in China

BeiGene, a Beijing biotech, announced China granted conditional approval for its PARP inhibitor, the company's third China approval. Pamiparib was approved as a third-line treatment for recurrent advanced ovarian, fallopian tube or primary peritoneal cancer with germline BRCA mutations. BeiGene said pamiparib is currently being tested in multiple global trials, including seven China trials for solid tumor malignancies. BeiGene plans a China launch for the PARP inhibitor this month. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.